Will Herrington discusses the rationale, design, results and conclusions of the EMPA-KIDNEY trial, which investigated the effects of empagliflozin in patients with CKD.

Worldwide, an estimated 850 million people have some form of kidney disease. Adeera Levin introduces the global burden of CKD and summarizes the benefits of SGLT2 inhibitors.

Find here the slides of the presentation by Natalie Staplin, titled "SGLT2i among patients with and without diabetes: collaborative meta-analysis of large placebo-controlled trials".

Find here the slides of the presentation by Meg Jardine, titled "SGLT2i in the spectrum of CKD: A call for action".

Find here the slides of the presentation by William Herrington, titled "The EMPA-Kidney trial: Broadening the evidence of SGLT2i in CKD".

Find here the slides of the presentation by Adeera Levin, titled "Introduction: New opportunities to tackle the global burden of CKD Role of SGLT2i".